Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

NCT03536767 is registered in ClinicalTrials.gov with Eidos Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT03536767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03536767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Phase
Phase 2
Overall status
Terminated
Start date
August 8, 2018
Completion date
September 15, 2025
Enrollment
47 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid cardiomyopathy